NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024
Rhea-AI Summary
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, has announced its plans to release second quarter 2024 financial results on August 13, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results.
Investors can access the live webcast at https://viavid.webcasts.com/starthere.jsp?ei=1677457&tp_key=a97b4f856d or join via telephone by dialing +1-877-407-3982 (Conference ID: 13747326). The webcast will be archived on NeuroPace's investor relations website for at least 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – NPCE
On the day this news was published, NPCE declined 4.61%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2024 after market close on Tuesday, August 13, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1677457&tp_key=a97b4f856d. Individuals interested in participating in the call via telephone may access the call by dialing +1-877-407-3982 and referencing Conference ID 13747326. The webcast will be archived on the company’s investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When will NeuroPace (NPCE) report its Q2 2024 financial results?
How can investors access NeuroPace's (NPCE) Q2 2024 earnings call?
What time is NeuroPace's (NPCE) Q2 2024 earnings conference call scheduled for?
Where can investors find the archived webcast of NeuroPace's (NPCE) Q2 2024 earnings call?
